Abstract
Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Current Pharmaceutical Design
Title:Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond
Volume: 22 Issue: 42
Author(s): Amine Benyamina, Laurent Karila, Geneviève Lafaye and Lisa Blecha
Affiliation:
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Abstract: Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Export Options
About this article
Cite this article as:
Benyamina Amine, Karila Laurent, Lafaye Geneviève and Blecha Lisa, Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond, Current Pharmaceutical Design 2016; 22 (42) . https://dx.doi.org/10.2174/1381612822666160831095707
DOI https://dx.doi.org/10.2174/1381612822666160831095707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Epigenetic Targets for Combating Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Technology-Dependent Children: The Chronically Ventilated Child
Current Pediatric Reviews Metabolism of Designer Drugs of Abuse
Current Drug Metabolism In Vitro Effects of Nickel on Healthy Non-Allergic Peripheral Blood Mononuclear Cells. The Role of Red Grape Polyphenols
Endocrine, Metabolic & Immune Disorders - Drug Targets Amyloid-beta Induced Neurotoxicity Impairs Cognition and Adult Hippocampal Neurogenesis in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke
Current Neurovascular Research Disorder in Milk Proteins: Caseins, Intrinsically Disordered Colloids
Current Protein & Peptide Science Reversal in Cognition Impairments, Cholinergic Dysfunction, and Cerebral Oxidative Stress Through the Modulation of Ryanodine Receptors (RyRs) and Cysteinyl Leukotriene-1 (CysLT1) Receptors
Current Neurovascular Research Convergence of PKC-Dependent Kinase Signal Cascades on NMDA Receptors
Current Drug Targets CYP1A1 and CYP2D6 Polymorphisms and Susceptibility to Chronic Myelocytic Leukaemia
Current Cancer Drug Targets The Role of Vasopressin in Affective Disorders: Possible Targets of Intervention
Central Nervous System Agents in Medicinal Chemistry Dopaminergic Enhancement of Cognitive Function
Current Pharmaceutical Design Foreword
Recent Patents on CNS Drug Discovery (Discontinued) Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Naturally Occurring Phenylethanoid Glycosides: Potential Leads for New Therapeutics
Current Medicinal Chemistry Autoantibody Reaction to Myelin Basic Protein by Plasma Parvovirus B19 IgG in MS Patients
Protein & Peptide Letters The Role of Oxidative Stress in Cerebral Aneurysm Formation and Rupture
Current Neurovascular Research The Impact of Physical Exercise on the Hippocampus in Physiological Condition and Ageing-Related Decline: Current Evidence from Animal and Human Studies
Current Pharmaceutical Biotechnology Overview of Experimental and Conventional Pharmacological Approaches in the Treatment of Sleep and Wake Disorders
Current Topics in Medicinal Chemistry